BIRMINGHAM, Ala. — August 6, 2026 — Rampart IC, Inc., the global leader in lead-free enhanced radiation protection devices (ERPD), today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Intent to Issue an Ex Parte Reexamination (EPR) Certificate (“the Notice”), upholding the validity of the claims of U.S. Patent No. 11,660,056 (“the ’056 Patent”) as amended. The upheld claims continue to protect Rampart’s radiation-shielding products and underscore the innovative nature of Rampart’s approach to protecting clinicians and medical teams from occupational radiation exposure.

“We are pleased that the patentability of Rampart’s claims has been confirmed,” said Tom Livingston, CEO of Rampart. “This outcome validates the strength of Rampart’s intellectual property and reflects the real-world innovation embodied in our products. Rampart remains committed to advancing radiation-protection solutions that support clinicians, patients, and healthcare institutions.”

The confirmed claims further strengthen Rampart’s intellectual property portfolio and reinforce the company’s ability to protect the innovations underlying its products. Rampart will continue to   invest in innovation directed to technologies that improve the safety and well-being of medical professionals.

About Rampart

Rampart is a Birmingham, Alabama–based medical device company redefining interventional radiation safety through rigorous clinical evidence. Supported by two randomized controlled trials and peer-reviewed real-world evidence in more than 1,700 procedures across 150+ sites, Rampart’s solutions deliver greater than 99% scatter radiation reduction and are proven to be up to 20x more effective than lead aprons and traditional shields.

Designed with zero pounds of wearable burden and engineered so that it adds no weight to the clinician or the procedure table, Rampart eliminates the orthopedic strain long associated with wearing lead aprons while preserving full procedural freedom. As the sole worldwide manufacturer of ClearShield® Technology — a proprietary lead-free bismuth acrylic that delivers consistent 1mm lead equivalency protection — Rampart is the only ERPD built from completely lead-free materials, supporting a more sustainable approach to radiation safety without compromises of traditional lead-based shielding.  Available nationwide and through global distribution partnerships, Rampart provides Total Body, Total Team Protection™ for every member of the interventional team – enabling clinicians everywhere to safely Shed the Lead®.